Abstract: Dabigatran was approved for the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF). However, the safety and efficacy of dabigatran for periprocedural anticoagulation in the setting of AF ablation are not well studied. This article reviews the safety and effectiveness of periprocedural dabigatran for anticoagulation in patients undergoing AF ablation.